Advertisement
Advertisement
GRFS
Grifois, S.A.
7.94
USDSponsored
+0.11
+1.40%
Aug 07, 15:59 UTC -4
Closed
After-Market
7.95
+0.01
+0.13%
GRFS Earnings Reports
Positive Surprise Ratio
GRFS beat 3 of 6 last estimates.
50%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Grifois, S.A. earnings per share and revenue
On Jul 28, 2026, GRFS reported earnings of 0.40 USD per share (EPS) for Q2 26, beating the estimate of 0.13 USD, resulting in a 204.65% surprise. Revenue reached 3.57 billion, compared to an expected 1.77 billion, with a 101.61% difference. The market reacted with a +1.88% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Relay Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.41
Surprise
-2.78%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Profound Medical Corp. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
$0.26
Surprise
+199.01%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
FAQ
What were Grifois, S.A.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Grifois, S.A. reported EPS of $0.40, beating estimates by 204.65%, and revenue of $3.57B, 101.61% above expectations.
How did the market react to Grifois, S.A.'s Q2 2026 earnings?
The stock price moved up 1.88%, changed from $8.00 before the earnings release to $8.15 the day after.
When is Grifois, S.A. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Grifois, S.A.'s next earnings report?
Based on --
analysts, Grifois, S.A. is expected to report EPS of -- and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement